2-(cyclopropylamino)-2-oxoacetic acid | 183235-79-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(cyclopropylamino)-2-oxoacetic acid
• CAS: 183235-79-2
• 化学式: C₅H₇NO₃
• mdl: MFCD10018376
• 分子量: 129.115
• InChiKey: OQMQLEHOJCDKHA-UHFFFAOYSA-N

物化性质

• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险类别：
  9
• 危险性防范说明：
  P260,P264,P273,P301+P312,P305+P351+P338,P314
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H319,H372,H410
• 包装等级：
  III
• 储存条件：
  存储条件：室温、密封、干燥

反应信息

• 作为反应物：
  描述：

  2-(cyclopropylamino)-2-oxoacetic acid 在 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 生成 N'-[(1S)-2-[[(1S)-1-[(2S,3aS,7aS)-2-[[(1S)-1-[2-(cyclopropylamino)-2-oxo-acetyl]butyl]carbamoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-1-carbonyl]-2,2-dimethyl-propyl]amino]-1-cyclohexyl-2-oxo-ethyl]-N-cyclopropyl-oxamide
  参考文献：
  名称：

  Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics

  摘要：

  Reversible tetrapeptide-based compounds have been shown to effectively inhibit the hepatitis C virus NS3 center dot 4A protease. Inhibition of viral replicon RNA production in Huh-7 cells has also been demonstrated. We show herein that the inclusion of hydrogen bond donors on the P4 capping group of tetrapeptide-based inhibitors result in increased binding potency to the NS3 center dot 4A protease. The capping groups also impart significant effects on the pharmacokinetic profile of these inhibitors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.090
• 作为产物：
  描述：

  2-(环丙基氨基)-2-氧代乙酸乙酯 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 2-(cyclopropylamino)-2-oxoacetic acid
  参考文献：
  名称：

  Hydrogen bond patterns in solid state carboxylic acids. Vibrational behaviour of the catamer pattern as exhibited by the N-alkyloxamic acids

  摘要：

  The vibrational study presented in this publication shows that the N-alkyloxamic acids are hydrogen bonded through a catamer hydrogen bond pattern in the solid state. Two different hydrogen bond patterns are possible for these products, and these patterns can be very clearly distinguished by their vibrational behaviour. Deuteration and low temperature spectra make the assignment and characterisation more obvious.

  DOI：

  10.1016/0584-8539(96)01689-3

文献信息

• Azabenzimidazole Compounds
  申请人：Pfizer Inc.

  公开号：US20140235612A1

  公开（公告）日：2014-08-21

  The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.

  本发明涉及以下化合物的公式I：或其药用可接受的盐，其中取代基如本文所定义。
• [EN] SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME<br/>[FR] AMIDES D'ISOQUINOLINYLMÉTHYLE SUBSTITUÉS, ANALOGUES DE CEUX-CI ET PROCÉDÉS LES UTILISANT
  申请人：ARBUTUS BIOPHARMA CORP

  公开号：WO2021250461A1

  公开（公告）日：2021-12-16

  The present disclosure includes substituted isoquinolinylmethyl amides, or analogues thereof, of formula (I), wherein the groups R1, R2, R3, R4a, R4b and R5 and variable p are as defined herein, and compositions comprising the same, that can be used to treat, ameliorate and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

  本公开涵盖了式(I)的取代异喹啉甲基酰胺或其类似物，其中所述的基团R1、R2、R3、R4a、R4b和R5以及变量p的定义如本文所述，并包括含有这些物质的组合物，可用于治疗、改善和/或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。
• Azabenzimidazole compounds
  申请人：Pfizer Inc.

  公开号：US09120788B2

  公开（公告）日：2015-09-01

  The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.

  本发明涉及式I的化合物：或其药学上可接受的盐，其中取代基如此定义。
• Minisci‐Type Carbamoylation of Azauracils with Oxamic Acids
  作者：Changduo Pan、Dongdong Chen、Miao Zeng、Haoyang Tian、Jin‐Tao Yu

  DOI：10.1002/ejoc.202301177

  日期：2024.2.19

  A Minisci‐type carbamoylation of azauracils was developed to afford 6‐carbamoyl azauracils in yields up to 94 %. In this transformation, oxamic acids were employed as the carbamoyl radical sources under metal‐free conditions. It features high atom economy, good functional group compatibility and convenient operation.

  摘要 研究人员开发了一种偶氮嘧啶的迷你型氨基甲酰化技术，可获得 6-氨基甲酰偶氮嘧啶，收率高达 94%。在这一转化过程中，氨基甲酰基来源是在无金属条件下使用的草酸。它具有原子经济性高、官能团兼容性好和操作方便等特点。
• Visible light mediated iron-catalyzed addition of oxamic acids to imines
  作者：Margaux Badufle、Frédéric Robert、Yannick Landais

  DOI：10.1039/d4ra02258k

  日期：2024.4.16

  be conducted using a 3-component strategy by simply mixing aldehydes, amines and oxamic acids in the presence of ferrocene, acting both as a photocatalyst under visible light and as a Lewis acid. The reaction proceeds through the addition onto the imine of a carbamoyl radical intermediate generated through a charge transfer from the carboxylate ligand to a Fe(III) species (LMCT).

  草酸可与亚胺加成，以通常良好的收率提供多种 α-氨基酸酰胺。该过程对于预形成的亚胺是有效的，但也可以使用三组分策略进行，通过在二茂铁存在下简单地混合醛、胺和草酰胺酸，既充当可见光下的光催化剂又充当路易斯酸。该反应通过将氨基甲酰自由基中间体加成到亚胺上来进行，该中间体是通过从羧酸配体到 Fe( III ) 物质 (LMCT) 的电荷转移而产生的。